Alexander Schuhmacher
Title
Dr.
Last Name
Schuhmacher
First name
Alexander
Email
alexander.schuhmacher@student.unisg.ch
Now showing 1 - 1 of 1
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Out-Licensing in Pharmaceutical Research and Development(Wiley-VCH, 2016); ; ; ;Gerrit ReepmeyerSeventy percent of pharmaceutical companies expect their collaborations will primarily take the traditional forms of out-licensing products or technology. Whereas research alliances, in-licensing, and co-development are quite established and traditional collaboration approaches, many established pharmaceutical companies have long considered out-licensing a difficult task. The purpose of this chapter is to illustrate how out-licensing by pharmaceutical companies can contribute to an increase in research and development (R&D) efficiency. A case study of Novartis demonstrates how the out-licensing can be successfully adopted and managed. Successfully executed out-licensing programs provide pharmaceutical firms with several benefits such as additional revenue generation, cost- and resource effectiveness, and mitigation of R&D related risks.Type:book section